Payer Perspectives on the Treatment Landscape of Spinal Muscular Atrophy (SMA) - Findings from the AMCP Market Insights Program
Webinar Recorded on June 17, 2020
Spinal muscular atrophy (SMA) is a rare, autosomal recessive genetic disease that causes progressive muscle weakness and atrophy. Approximately 6,000 children and adults in the United States are affected, making SMA one of the most common rare diseases. AMCP conducted a virtual Market Insights program to identify perspectives of AMCP members on current and future therapies for SMA. The Market Insights program offered by AMCP is a blinded research program sponsored by corporate member to address current conditions that are a high priority among the AMCP membership. This webinar reviews the key perspectives of the panel of AMCP members, as well as how the are responding to this dynamic category.
- Diana I. Brixner, RPh, PhD, FAMCP
Moderator of Market Insights Program
Professor, Department of Pharmacotherapy, University of Utah College of Pharmacy
Executive Director, Department’s Outcomes Research Center